In principle, BET inhibitors (BETi) as well may override resistance to MAPK inhibitors in certain tumors (such as NRAS-mutant melanoma) by sensitizing them to apoptosis and have been shown to potently inhibit growth of solid and hematological tumor cells in vitro and in vivo in animal models [50]. The gene discussed is NRAS; the disease is melanoma.